Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent protects the company’s use of artificial intelligence in its Nociscan platform, which analyzes magnetic resonance spectroscopy (MRS) data to help physicians locate the source of chronic low back pain.
The newly issued patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. It also includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability is designed to ensure consistent, reproducible outputs across different imaging systems and clinical sites, a key step toward broader adoption in routine practice.
Brent Ness, Chief Executive Officer of Aclarion, stated, “This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice. By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent expands Aclarion’s intellectual property portfolio to 64 issued and pending patents worldwide. The company’s cloud-based platform, Nociscan, converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. Chronic low back pain affects approximately 266 million people globally, and when used alongside other diagnostic tools, clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated.
To read the full patent, click here. For more information about Aclarion and Nociscan, visit the company’s website.
